Pan-resistant organism as per culture report with evidence of invasive disease – fever/ leucocytosis/elevated procalcitonin (PCT) or culture from a sterile site.
Clinical failure of all other classes of antibiotics over 72 hours
Cefepime-tazobactam is currently under clinical development at 2g/2g q8 hours as well as q12 hours dosage as a 90 minute infusion
Empirical treatment for febrile neutropenia
Moderate to severe pneumonia
Complicated intra-abdominal infections
Skin and skin structure infections
Cefepime-Tazobactam demonstrated activity against a large collection of antimicrobial-resistant Enterobacteriaceae strains and pseudomonas. It exhibited a spectrum of activity comparable to meropenem which is significantly superior to piperacillin-tazobactam
and cefepime, and can potentially be used as a carbapenem sparing agent.
Efedra Pharmaceuticals Pvt. Ltd.
New logo in critical care market with innovative products.